Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
27 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Hyloris Pharmaceuticals from Liège, company number BE0674494151, closed financial year 2025 with a result of € -1.2 million after tax. For that financial year Hyloris Pharmaceuticals recorded revenue of € 3.8 million and equity of € 87.2 million. Compared with financial year 2024, the result moved from € -14.4 million to € -1.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
€ 87.2 million
▼ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.2 million
▲ 92 % less loss than in 2024
Profit after tax over the fiscal year.
€ 11.7 million
▼ 48% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -34.5 million.
People and assets in 2025
3.4
▲ 1.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 480,074
▲ 153% vs 2024
€ 141,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3.9 million
▲ 25% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 207 days on average.
€ 81,958
▲ 82% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,204,885 | € 1,120,551 | € 5,966,698 | € 3,817,735 | ▼ 36% |
| Profit after taxes | € -903,445 | € -3,402,312 | € -14,391,206 | € -1,205,801 | ▲ € 13.2 million |
| Equity | € 106,320,976 | € 102,751,874 | € 88,360,668 | € 87,154,867 | ▼ 1% |
| Total debts | € 11,509,814 | € 11,952,617 | € 6,917,536 | € 14,377,731 | ▲ 108% |
| Cash | € 4,589,023 | € 18,817,284 | € 22,390,031 | € 11,674,055 | ▼ 48% |
| Retained profit | € -15,332,473 | € -18,901,575 | € -33,292,781 | € -34,498,582 | ▼ € 1.2 million |
| Bank debt | € 6,633,479 | € 4,287,460 | € 0 | € 0 | |
| Balance sheet total | € 117,830,790 | € 114,704,491 | € 95,663,227 | € 101,532,598 | ▲ 6% |
| Employees (FTE) | 0.9 | 2.5 | 1.9 | 3.4 | ▲ 1.5 |
Key figures of Hyloris Pharmaceuticals, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Hyloris Pharmaceuticals?
What happened at Hyloris Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Biofinance Consulting BV stepped down as director. NBB
- Jacobsen Management SRL stepped down as director. NBB
- Sybefica Invest SPRL stepped down as director. NBB
- SVR Management SRL stepped down as director. NBB
- Stefan Yee stepped down as director. NBB
- IRYL Partners SAS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.2 million. Source: NBB ↗
- Biofinance Consulting BV became a director. NBB
In short
From € 903,445 loss in 2022 to € 1.2 million loss in 2025.
Paid € 16,659 in corporate taxes since 2022.
Management
The stake of DVP Invest comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Hyloris PharmaceuticalsThe shares are held by Stijn Van Rompay (27.7%), Thomas Jacobsen (12.3%), Scorpiaux BV (6.2%), Nick Reunbrouck (5.8%), Pieter Van Rompay (3.3%) and Dietmar Aichhorn (0.1%). It owns 100% of Hyloris Developments, 100% of Hyloris Therapeutics, 100% of Dermax, 100% of Hyloris SA and 20% of FHP itself.
Directors
According to the 2025 annual accounts
Director · represented by Mélanie Mestdagt
since 2025 · until 2028
Managing director · represented by Thomas Jacobsen
Also active at: Hyloris Developments, DERMAX, Hyloris
since 2024 · until 2028
Director · represented by Vincent Van Dessel
since 2025 · until 2028
Managing director, Director · represented by Stijn Van Rompay, Léon Van Rompay
Also active at: Hyloris Developments, DERMAX, Hyloris
since 2024 · until 2028
Stefan Yee
Chairman of the board
Also active at: AED DISTRIBUTION, AED Rent, MARREYT CLASSICS, HELIVENTURE FTO, AS Partners, WIISH, STOLP, Axiles Bionics +16 more
since 2024 · until 2028
Director · represented by Revital Rattenbach
since 2025 · until 2028
Shareholders
Stijn Van Rompay
27.7%
Thomas Jacobsen
12.3%
6.2%
Nick Reunbrouck
5.8%
Pieter Van Rompay
3.3%
Dietmar Aichhorn
0.1%
1%
Participations
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 27 companies are registered at this address.
All companies at this address →EYED PHARMA
€ 10.5 million revenue · 2025
Hyloris Developments same network
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX same network
€ 1.6 million revenue · 2025
Hyloris same network
€ 384,852 revenue · 2025
+22 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0674.494.151
- VAT number
- BE 0674.494.151
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 1, 4000 Liège
- Names & denominations
- Hyloris Pharmaceuticals · Hyloris
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 April 2017
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Activiteiten van holdings
Overige zakelijke dienstverlening, neg
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van hoofdkantoren
Vervaardiging van farmaceutische grondstoffen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
+1